Adv Med Sci. 2022 Jan 28;67(1):95-102. doi: 10.1016/j.advms.2022.01.003. Online ahead of print.
BACKGROUND: Patients with acute decompensated heart failure (ADHF) are at severe risk of death and rehospitalization. Several clinical studies have been designed to evaluate the efficacy and safety of new molecules administered before discharge or shortly after ADHF. The aim of this article is to summarize current knowledge on recently published findings on treatment of patients with heart failure with reduced ejection fraction (HFrEF) and ADHF.
METHODS: We performed a thorough search for literature pertaining to our review via the PubMed database.
RESULTS: In this review, we summarize original papers concerning the efficacy and safety of new molecules in patients with HFrEF and ADHF.
CONCLUSIONS: Peri-discharge initiation of treatment with new molecules is possible and safe for patients with HFrEF and ADHF. New molecules, if administered before discharge or shortly after, reduce the risk of cardiovascular death or worsening heart failure within the vulnerable phase, and are also nephroprotective.